氨基观察-创新药组原创出品作者 | 沙晓威曾经跌落谷底的肿瘤免疫“终极武器”,正以更科学的姿态卷土重来。20多年前,癌症疫苗承载着攻克肿瘤的厚望,全球超百款项目同时推进。然而,这样的辉煌并未持续太久。2010年,首款获批的癌症治疗性疫苗Provenge,由于没能带来颠覆性的疗效,销量不佳,最终惨淡收场,其研发公司Dendreon也因此破产。Provenge没能带领癌症疫苗走向新纪元,更遗憾的是,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.